Hsbc Holdings PLC Catalyst Pharmaceuticals, Inc. Transaction History
Hsbc Holdings PLC
- $168 Billion
- Q3 2024
A detailed history of Hsbc Holdings PLC transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Hsbc Holdings PLC holds 22,068 shares of CPRX stock, worth $474,903. This represents 0.0% of its overall portfolio holdings.
Number of Shares
22,068
Previous 32,902
32.93%
Holding current value
$474,903
Previous $509,000
13.95%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding CPRX
# of Institutions
326Shares Held
94MCall Options Held
19.1KPut Options Held
51.1K-
Black Rock Inc. New York, NY18.7MShares$402 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.04MShares$173 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY6.23MShares$134 Million2.3% of portfolio
-
State Street Corp Boston, MA5.69MShares$122 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.02MShares$65 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.21B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...